Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.
Methods: 78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients.
Results: Our results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients.
Conclusion: CD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL.
Clinical Trial Registration: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926187 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1293931 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC.
Mol Cancer
June 2025
The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Jinan University, Guangzhou, 510317, China.
Background: The immunological landscape of metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC) is not well understood. Herein, we aim to delineate the immunological landscape in the MASH-to-HCC transition and to identify the critical genes that contribute to the pathogenesis of MASH-related HCC.
Methods: A well-established MASH-driven HCC mouse model, STAM model, was first constructed.
Distinct Activation and Functional Features of CD307c T Lymphocytes in Peripheral Blood as Diagnostic and Prognostic Markers in Breast Cancer.
Immunology
October 2025
Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
This study aims to investigate the expression and role of CD307c in the breast cancer (BC) microenvironment, T lymphocytes of peripheral blood, particularly in BC patients at various stages, and assess its potential as a clinical diagnostic biomarker. Bioinformatics analysis was performed to investigate CD307c expression. As experimental validation, a total of 54 BC patients and 44 healthy controls (HCs) were enrolled.
View Article and Find Full Text PDFImmunometabolic changes and potential biomarkers in CFS peripheral immune cells revealed by single-cell RNA sequencing.
J Transl Med
October 2024
Department of Endocrinology and Metabolism, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, 250012, China.
Article Synopsis
- The study investigates the immune and metabolic profiles of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) using single-cell RNA sequencing of blood cells from patients and healthy controls, revealing significant cellular composition changes.
- It shows an increase in T cells but a notable decrease in other immune cells like NKs and monocytes, suggesting complex alterations in immune function among ME/CFS patients.
- The research identifies potential biomarkers and pathways, such as ESRRA-APP-CD74, linking immune dysfunction to neurological symptoms, hinting at the disease's autoimmune and immunodeficiency aspects.
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Front Immunol
March 2024
Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain.
Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need.
View Article and Find Full Text PDFComprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
BMC Cancer
January 2024
Department of Thoracic Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Background: Mitochondria, which serve as the fundamental organelle for cellular energy and metabolism, are closely linked to the growth and survival of cancer cells. This study aims to identify and assess Sideroflexin1 (SFXN1), an unprecedented mitochondrial gene, as a potential prognostic biomarker for lung adenocarcinoma (LUAD).
Methods: The mRNA and protein levels of SFXN1 were investigated based on the Cancer Genome Atlas (TCGA) LUAD dataset, and then validated by real-time quantitative PCR, Western Blotting and immunohistochemistry from our clinical samples.